This fund takes an inverse leveraged position in a group of biotechnology and pharmaceutical companies listed on the Nasdaq exchange. It aims to deliver daily returns that move in the opposite direction of its target index, using at least 80% of its assets to achieve this exposure. The fund concentrates its holdings rather than spreading risk across a broad range of investments.
